Patents Examined by Brian Gangle
  • Cytokine combination
    Patent number: 11535656
    Abstract: Provided is a cytokine combination for treating a tumor and/or preventing recurrence or metastasis of the tumor. The cytokine combination comprising at least three cytokines selected from the following groups: IL(interleukin)12 or a functional variant thereof, GMCSF (granulocyte-macrophage colony-stimulating factor) or a functional variant thereof, FLT3L (FMS-like tyrosine kinase 3 ligand) or a functional variant thereof, IL2 or a functional variant thereof, IL15 or a functional variant thereof, IL21 or a functional variant thereof, and IL7 or a functional variant thereof. Also provided is a nucleic acid molecule encoding the cytokine combination and a vector thereof, a cell, a pharmaceutical composition, and a application thereof for the manufacture of a drug for treating the tumor and/or preventing recurrence or metastasis of the tumor.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: December 27, 2022
    Inventor: Jinyu Zhang
  • Telomerase polypeptide vaccine for treating cancer
    Patent number: 11529403
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: December 20, 2022
    Assignee: ULTIMOVACS AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
    Patent number: 11529379
    Abstract: A method for reducing the likelihood of an individual developing colorectal cancer includes the use of a CRISPR system to selectively kill pathogenic bacteria, such as Klebsiella and E coli, within the individual. Preferrably, the growth of a beneficial bacteria, such as Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and Streptococcus bacteria, is also enhanced. Reduction of certain virulence factors, such as colibactin, using a CRISPR system, as well the employment of immune checkpoint inhibitors, is effective in treating individuals with cancer and who suffer from a chronic infectious disease.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: December 20, 2022
    Assignee: SEED HEALTH, INC.
    Inventor: Joseph E. Kovarik
  • MDR immunogen
    Patent number: 11529405
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: December 20, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Eszter Nagy, Gäbor Nagy, Valéria Szijárto, Zóltan Magyarics, Irina Mirkina, Luis Gauchalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Bacterial extracellular vesicles
    Patent number: 11524037
    Abstract: Provided herein are methods and compositions related to EVs useful as therapeutic agents.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: December 13, 2022
    Assignee: Evelo Biosciences, Inc.
    Inventors: Brian Goodman, Baundauna Bose, Christopher J. H. Davitt
  • Methods of vaccine administration
    Patent number: 11524067
    Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: December 13, 2022
    Assignee: Zoetis Services LLC
    Inventors: Cassius McAllister Tucker, John David Haworth
  • Poultry vaccine for clostridium perfringens
    Patent number: 11524061
    Abstract: The present disclosure relates to nanoparticle compositions for use as vaccines against Clostridium perfringens in poultry which causes necrotic enteritis in poultry. Such compositions include one or more Clostridium perfringens extracellular proteins entrapped in a polyanhydride or chitosan nanoparticle. The one or more Clostridium perfringens extracellular proteins may include one or more Clostridium perfringens toxins, such as, for example, alpha toxin (CPA), beta toxin (CPB), epsilon toxin (ETX), iota toxin (ITX), perfringolysin O (PFO), enterotoxin (CPE), beta2 toxin (CPB2), or NetB toxin. In some aspects, the composition further includes a Salmonella enteritidis flagellar protein. The present invention also includes methods for the oral delivery of one or more Clostridium perfringens extracellular proteins to the mucosal membrane of the intestinal tract of a bird of the order Galliformes.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: December 13, 2022
    Assignees: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC, THE OHIO STATE UNIVERSITY
    Inventors: Ramesh Kumar Selvaraj, Gabriel Akerele, Sankar Renu, Renukaradhya J. Gourapura
  • IL-37 fusion protein and methods of making and using same
    Patent number: 11524985
    Abstract: The disclosure provides interleukin 37 (IL-37) fusion proteins, methods of making IL-37 fusion proteins including constructs used to express IL-37 fusion proteins, and methods of using IL-37 fusion proteins. In some embodiments, the IL-37 fusion protein includes amino acids 46-206 of isoform B of IL-37 and a heavy chain portion of an antibody.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: December 13, 2022
    Assignees: Bio-Techne Corporation, The Regents of the University of Colorado
    Inventors: Vassilios Kalabokis, Charles A. Dinarello
  • Methods of vaccine administration
    Patent number: 11524068
    Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: December 13, 2022
    Assignee: Zoetis Services LLC
    Inventors: Cassius McAllister Tucker, John David Haworth
  • Oral dispersible vaccine comprising virosomes
    Patent number: 11523988
    Abstract: The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: December 13, 2022
    Assignees: Catalent U.K. Swindon Zydis Limited, Mymetics Corporation
    Inventors: Yik Teng Wong, Charli Smardon, Khojasteh Shirkhani, Mario Amacker, Sylvain Fleury, Antonius Johannes Hendrikus Stegmann
  • Treatment of severe community acquired pneumonia
    Patent number: 11517621
    Abstract: The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: December 6, 2022
    Assignee: BIOTEST AG
    Inventors: Patrick Langohr, Andrea Wartenberg-Demand, Ulrike Wippermann, Benjamin Daelken
  • Chromatography ligand comprising domain C from protein A for antibody isolation
    Patent number: 11517879
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: December 6, 2022
    Assignee: CYTIVA BIOPROCESS R&D AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Anti-angiogenesis fusion protein and uses thereof
    Patent number: 11518819
    Abstract: The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fragment crystallizable region (Fc) is an N-terminal of Immunoglobulin G (IgG); each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: December 6, 2022
    Assignee: TRICAN BIOTECHNOLOGY CO., LTD
    Inventors: Huang-Tsu Chen, Jiun-Shyang Leou, Chung-Yuan Hsu, Cheng-Ke Li, Yun-Ting Wang, Li-Tsen Lin
  • Compositions comprising bacterial strains
    Patent number: 11504405
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing lung injury or lung disease.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: November 22, 2022
    Assignee: 4D Pharma Research Limited
    Inventors: Imke Mulder, Alexander Stevenson, Helene Savignac
  • Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology
    Patent number: 11504408
    Abstract: A method for treating autoimmune and/or inflammatory disease includes a step of identifying a subject exhibiting symptoms of autoimmune and/or inflammatory disease administering a fasting mimicking diet. A probiotic composition for gastrointestinal autoimmune and/or inflammatory disease Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof is also provided.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: November 22, 2022
    Assignee: University of Southern California
    Inventors: Valter D. Longo, Min Wei, Priya Rangan
  • Antigenic tripeptides derived from subsp. s-type strains, derivatives and uses thereof
    Patent number: 11498942
    Abstract: The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 15, 2022
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: John P. Bannantine, Gilles Etienne, Sylvie Bay, Franck Biet
  • Parathyroid hormone-anti-RANKL antibody fusion compounds
    Patent number: 11492386
    Abstract: Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: November 8, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Andrew H Korytko, Yanfei L Ma, Amita Datta-Mannan, Victor H Obungu
  • Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria
    Patent number: 11491192
    Abstract: A method of treating or preventing overgrowth by pathogenic bacteria in a subject deficient in butyrate and/or butyrate-producing bacteria in their gut microbiota by administering a therapeutically effective amount of a butyrate-producing bacteria to the subject is described. A prebiotic can be included with the butyrate-producing bacteria. Overgrowth by pathogenic bacteria is commonly caused by antibiotic administration.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: November 8, 2022
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventor: Gail Cresci
  • Anti-PCSK9 antibody and use thereof
    Patent number: 11485795
    Abstract: The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and fragment in treatment and diagnosis.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: November 1, 2022
    Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD
    Inventors: Andy Tsun, Eric Krauland, Jonathan P Belk, Xiaoniu Miao, Min Zhang, Nadthakarn Boland, Xiaolin Liu, Dechao Yu
  • Polymeric nanoparticles providing nucleic acids encoding TNF-?
    Patent number: 11484507
    Abstract: The present invention relates to polymeric nanoparticles comprising a cytokine or a nucleic acid encoding for a cytokine, pharmaceutical compositions comprising the same, and methods for treating certain diseases comprising administering these polymeric nanoparticles to a subject in need thereof.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: November 1, 2022
    Assignee: Hillstream BioPharma, Inc.
    Inventors: Surender Kharbanda, Vasundhara Shukla, Donald Kufe, Harpal Singh